Chrome Extension
WeChat Mini Program
Use on ChatGLM

Tacrolimus Induces Short‐term but Not Long‐term Clinical Response in Inflammatory Bowel Disease

Alimentary Pharmacology and Therapeutics(2020)SCI 1区

Hosp Galdakao Usansolo | Hosp Clin Barcelona | Hosp Univ Ramon y Cajal | Hosp del Mar | Hosp Badalona Germans Trias & Pujol | Complejo Hosp Navarra | Hosp Univ Cruces | Hosp Univ Puerta Hierro | Hosp Santa Creu & Sant Pau | Hosp Univ Miguel Servet | Hosp Univ Princesa | Hosp Clin Univ Santiago de Compostela | Hosp Montecelo | Hosp Univ Reina Sofia | Hosp Clin San Carlos | Hosp Univ Marques de Valdecilla | Hosp Univ La Paz | Hosp Galdakao | Hosp Univ La Princesa

Cited 11|Views22
Abstract
Background Tacrolimus is a calcineurin inhibitor commonly used for prophylaxis of rejection in renal and liver transplantation. There are limited but favourable data regarding its possible use in patients with inflammatory bowel disease (IBD). Aims To evaluate the efficacy and safety of tacrolimus in patients with IBD in clinical practice. Methods We performed a retrospective, multicentre study in 22 centres in Spain. All adult patients who received oral tacrolimus for luminal or perianal IBD were included. Clinical response was assessed by Harvey-Bradshaw index and partial Mayo score after 3 months. Perianal disease was evaluated by fistula drainage assessment. Results One hundred and forty-three patients were included (mean age 38 years; 51% male; median disease duration 110 months). In ulcerative colitis (UC) (n = 58), the partial Mayo score decreased after 3 months from median 6 to 3 (P = 0.0001), whereas in Crohn's disease (CD) (n = 85), the Harvey-Bradshaw index decreased after 3 months from median 9 to 7 (P = 0.011). In CD patients, blood tacrolimus concentrations during induction (>10 ng/mL vs <10 ng/mL; odds ratio 0.23, 95% CI 0.05-0.87) and the concomitant use of thiopurines (odds ratio 0.18, 95% CI 0.04-0.81) were associated with lower clinical disease activity at 3 months. Of 62 patients with perianal disease, complete closure was observed in 8% (n = 5) of patients with perianal fistulas, with 34% (n = 21) showing partial response. Treatment was maintained for a median of 6 months (IQR, 2-16). After a median clinical follow-up of 24 months (IQR, 15-57), the rate of treatment-related adverse events was 34%, correlating with blood drug concentrations (P = 0.021). Finally, 120 patients (84%) discontinued tacrolimus, usually due to absence or loss of response. Three patients (2%) were subsequently diagnosed with cancer. The overall rate of surgery was 39%, with a 33% colectomy rate in UC. Conclusions Tacrolimus shows a clinical benefit in both CD and UC after 3 months of treatment, but its long-term effectiveness and frequent adverse events remain relevant issues in clinical practice.
More
Translated text
Key words
Therapies
求助PDF
上传PDF
Bibtex
AI Read Science
AI Summary
AI Summary is the key point extracted automatically understanding the full text of the paper, including the background, methods, results, conclusions, icons and other key content, so that you can get the outline of the paper at a glance.
Example
Background
Key content
Introduction
Methods
Results
Related work
Fund
Key content
  • Pretraining has recently greatly promoted the development of natural language processing (NLP)
  • We show that M6 outperforms the baselines in multimodal downstream tasks, and the large M6 with 10 parameters can reach a better performance
  • We propose a method called M6 that is able to process information of multiple modalities and perform both single-modal and cross-modal understanding and generation
  • The model is scaled to large model with 10 billion parameters with sophisticated deployment, and the 10 -parameter M6-large is the largest pretrained model in Chinese
  • Experimental results show that our proposed M6 outperforms the baseline in a number of downstream tasks concerning both single modality and multiple modalities We will continue the pretraining of extremely large models by increasing data to explore the limit of its performance
Upload PDF to Generate Summary
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Related Papers
H. Ogata, T. Matsui, M. Nakamura, M. Iida,M. Takazoe, Y. Suzuki,T. Hibi
2006

被引用367 | 浏览

Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn
Chat Paper

要点】:研究评估了他克莫司在临床实践中治疗炎症性肠病患者的有效性和安全性,发现其具有短期疗效但长期效果不佳。

方法】:采用回顾性、多中心研究方法,在西班牙22个中心对口服他克莫司治疗的患者进行了分析。

实验】:共纳入143名成年患者,通过Harvey-Bradshaw指数和部分Mayo评分评估了3个月后的临床反应,并使用了他克莫司血药浓度和硫唑嘌呤类药物的并用情况分析。结果显示,短期内有临床改善,但长期疗效和不良反应问题显著,最终84%的患者停止使用他克莫司。数据来源于西班牙22个中心的患者记录,未特别提及数据集名称。